Vancouver, BC — July 16, 2025 — Telescope Innovations Corp. (“Telescope” or the “Company”) (CSE: TELI) (OTCQB: TELIF) (FSE:J4U), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended May 31, 2025 (Q3). The Company generated revenues of $1.4 million during this period, and an adjusted EBITA loss of $0.1 million. Revenues were driven strongly by sales of DirectInject-LC™, our flagship product for advanced chemical analysis. Increased sales and revenues continue to fuel growth, with financial results in line with FY 2025 budget and targets.
FINANCIAL HIGHLIGHTS OF THE FISCAL QUARTER ENDED FEBRUARY 28, 2025
All values are represented in CAD.
- Revenues of $1,394,542 (versus $1,224,351 for the comparable quarter in FY 2024)
- Expenses of $1,896,028 (versus$1,424,650 for the comparable quarter in FY 2024)
- Adjusted EBITA loss of $99,466 (versus $51,413 EBITA loss for the comparable quarter in FY 2024)
OPERATIONAL HIGHLIGHTS
-
- STRONGEST QUARTER YET FOR DIRECTINJECT-LC PRODUCT™. Both sales and order pipelines enjoyed consistent growth this quarter, with the number of opportunities more than doubling compared to Q3, 2024. The recent launch in Asia rapidly converted into sales and deployed units in Japan, alongside a pipeline including multi-system orders in China. We continue working strategically with Mettler Toledo on our global distribution campaign: this quarter we executed 11 application feasibility studies at customer sites across the US, Europe, and Asia; participated in 2 lead-generating InfoDays hosted by Mettler Toledo; and presented at the 2025 IFPAC global conference, one of the largest Process Technology summits in North America.
-
- PROGRESS ON SELF-DRIVING LAB DEVELOPMENT WITH PFIZER. Telescope is in the final stage of building and confirmation testing a “Phase 1” Self-Driving Lab (SDL) platform in collaboration with Pfizer. SDLs use artificial intelligence, robotic automation, and advanced process analytical technology to perform chemistry research up to 100x than traditional methods. We are currently discussing the specifications of Phase 2 deliverables to ensure direct alignment of Telescope’s technology with industry needs.
- COMMERCIAL ADVANCEMENT OF LITHIUM SULFIDE (Li₂S) PRODUCTION TECHNOLOGY. Telescope shipped its first battery-grade Li₂S samples to major battery industry groups in Asia and North America, marking the initial customer evaluation of its proprietary low-temperature production process. The samples were made with North American feedstocks, including lithium hydroxide monohydrate from Standard Lithium Ltd.’s demonstration plant in southwest Arkansas. Building on this strategic collaboration, Telescope is now part of the inaugural cohort of the first US-based accelerator innovating the battery supply chain: the Arkansas Lithium Technology Accelerator.
“Q3 was marked by strong commercial momentum across our core technologies,” said Henry Dubina, Telescope CEO. “Telescope’s advanced analytical and automation innovations continue to gain traction with growing DirectInject-LC sales, our leadership in Self-Driving Labs, and the lithium processing technologies we developed with these tools. We’re excited to build on our partnerships Mettler Toledo, Pfizer, and Standard Lithium that are positioning us for long-term success.”
Readers are encouraged to review the full financial statements and accompanying management discussion and analysis for the fiscal year ended May 31, 2025, both of which are available under the profile for the Company on SEDAR+ (www.sedarplus.ca).
About Telescope Innovations
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.
On behalf of the Board,
Telescope Innovations Corp.
Henry Dubina, Chief Executive Officer
Forward-Looking Information
The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain certain “forward-looking information” under applicable Canadian securities laws. When or if used in this news release, the words “anticipate,” “believe,” “estimate,” “expect.” “target”, “plan,” “forecast,” “may,” “schedule,” and similar words or expressions identify forward-looking information. This forward-looking information may relate to planned project development, exploration programs, the intended use of the proceeds from the Offering and other factors or information.
Forward-looking information is based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information.
The forward-looking information contained in this news release is made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
